Glioblastoma
Conditions
Keywords
glioblastoma, GBM, immunotherapy, autologous lymphoid effector cells specific against tumour cells, ALECSAT, Stupp regimen, TMZ, radiotherapy
Brief summary
This is a randomised, open-label, multi-centre, Phase II study in patients with newly diagnosed glioblastoma. 62 patients with newly diagnosed glioblastoma are enrolled in the study in a 1:2 allocation (standard of care (SOC): ALECSAT as an adjunct therapy to SOC). Patients recruited into this study will receive either: * ALECSAT as an adjunct therapy to standard of care for newly diagnosed glioblastoma (first line therapy: Stupp regimen, followed by second line therapy at the Investigator's discretion) or * Standard of care therapy for newly diagnosed glioblastoma (first line therapy: Stupp regimen, followed by second line therapy at the Investigator's discretion).
Interventions
BIOLOGICALALECSAT
3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
RADIATIONRadiotherapy
Radiotherapy 5 days/week for 6 weeks
DRUGTemozolomide
Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
Sponsors
CytoVac A/S
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
open label
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Male or female patients, aged between 18 and 70. * Histologically confirmed glioblastoma (Grade IV) diagnosis. * Eligible for combined radiotherapy and TMZ treatment. * Patients with complete or partial tumour resection. For patients with limited tumour volume, biopsy is acceptable. * WHO Performance status 0-2. * Body weight ≥ 40 kg (males), ≥ 50 kg (females). * Able and willing to provide written informed consent and comply with the study protocol and procedures. * Women of child-bearing potential must have a negative pregnancy test at screening and agree to use acceptable methods of contraception during the trial.
Exclusion criteria
* Prior treatment for brain tumours at study entry. * Prior treatment with temozolomide at study entry. * Females who are pregnant, planning to become pregnant or breastfeeding. * Positive tests for anti- human immunodeficiency virus (HIV)-1/2; HBsAg, anti HBc, anti-HCV or being positive in a Treponema Pallidum test (syphilis). * Patients who may have been exposed to West Nile virus or Dengue fever virus within the last 28 days prior to enrolment or Ebola virus within the last 60 days prior to enrolment should be excluded, unless the patient has been tested negative. * Patients from high incidence areas for Human T-Lymphotropic Virus (HTLV-1) virus or who has a parent or spouse from a high incidence area must be excluded unless tested negative for HTLV-1 virus. * Known allergy to study medication. * Any condition or illness that, in the opinion of the Investigator or medical monitor, would compromise patient safety or interfere with the evaluation of the safety of the investigational drug. * Any concurrent illness that may worsen or cause complications in connection with blood donation, for example uncontrolled epilepsy, cardiovascular, cerebrovascular or respiratory disease. * Use of immunosuppressant drugs with the exception of steroids. Blood transfusion within 48 hours prior to the donation of blood for ALECSAT production. * Low haemoglobin count in the opinion of the Investigator. * Lymphocyte count \<0.3 x 109/litre. * Participation in any other interventional clinical trial within 30 days prior to inclusion. * TMZ contraindication.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 24 months after LPFV or when 47 patients has reached investigator assessed disease progression or death from any cause | Compare the progression free survival between patients who receive ALECSAT as add on to SoC and patients who only receive SoC |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of patients alive at 12 and 24 months | 24 months after LPFV or when 47 patients has reached investigator assessed disease progression or death from any cause | To compare OS rate at 12 and 24 months between patients who receive ALECSAT as add on to SoC and patients who only receive SoC |
| Frequency and Severity of treatment related Adverse Events | Up to 24 months after randomisation of last patient | Comparison of frequency and severity of treatment related AEs in the 2 study groups |
Countries
Sweden
Outcome results
None listed